Profile data is unavailable for this security.
About the company
Cibus, Inc. is an agricultural technology company that uses gene editing technologies to develop plant traits in seeds. Its business is the development of plant traits that help address specific productivity or yield challenges in farming, such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate. It is also engaged in developing, certain alternative plant-based oils or bio-based fermentation products. Its technology is its gene editing platform called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits, four of which are applicable to multiple crops. These traits are PSR in Canola and HT1 and HT3 in rice. In addition, it also has two advanced traits for Sclerotinia resistance and another novel broadleaf HT trait, HT2.
- Revenue in USD (TTM)2.32m
- Net income in USD-285.67m
- Incorporated2010
- Employees183.00
- LocationCibus Inc6455 Nancy Ridge DriveSAN DIEGO 92121United StatesUSA
- Phone+1 (858) 450-0008
- Fax+1 (302) 636-5454
- Websitehttps://calyxt.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurogene Inc | 0.00 | -39.03m | 437.70m | 91.00 | -- | 2.54 | -- | -- | -4.58 | -4.58 | 0.00 | 13.28 | 0.00 | -- | -- | 0.00 | -26.57 | -32.70 | -28.41 | -34.73 | -- | -- | -- | -- | -- | -- | 0.0006 | -- | -- | -- | 36.90 | -- | 45.63 | -- |
| PepGen Inc | 0.00 | -80.33m | 442.13m | 64.00 | -- | 2.47 | -- | -- | -3.25 | -3.25 | 0.00 | 5.53 | 0.00 | -- | -- | 0.00 | -39.37 | -- | -42.42 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
| Cibus Inc | 2.32m | -285.67m | 453.51m | 183.00 | -- | 1.39 | -- | 195.48 | -18.29 | -18.29 | 0.1522 | 13.24 | 0.0084 | -- | -- | 12,677.60 | -129.84 | -86.28 | -147.90 | -96.45 | -- | -- | -15,483.49 | -792.07 | -- | -3.17 | 0.0039 | -- | 1,057.33 | 50.41 | -1,484.44 | -- | 18.53 | -- |
| ACELYRIN Inc | 0.00 | -240.16m | 457.97m | 130.00 | -- | 0.7107 | -- | -- | -2.59 | -2.59 | 0.00 | 6.52 | 0.00 | -- | -- | 0.00 | -48.23 | -- | -52.78 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
| Biomea Fusion Inc | 0.00 | -127.27m | 459.37m | 110.00 | -- | 3.39 | -- | -- | -3.57 | -3.57 | 0.00 | 3.77 | 0.00 | -- | -- | 0.00 | -90.54 | -- | -107.35 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
| Lexeo Therapeutics Inc | 0.00 | -69.42m | 461.89m | 58.00 | -- | 2.52 | -- | -- | -2.71 | -2.71 | 0.00 | 5.56 | 0.00 | -- | -- | 0.00 | -47.71 | -- | -54.30 | -- | -- | -- | -- | -- | -- | -- | 0.0091 | -- | -100.00 | -- | -12.01 | -- | -- | -- |
| Theravance Biopharma Inc | 61.51m | -44.77m | 466.18m | 99.00 | -- | 2.28 | -- | 7.58 | -0.861 | -0.861 | 1.19 | 4.22 | 0.1352 | -- | 4.57 | 621,313.10 | -9.84 | -40.51 | -10.39 | -48.50 | -- | -- | -72.78 | -305.27 | -- | -- | 0.00 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| Cartesian Therapeutics Inc | 25.91m | -254.87m | 468.75m | 38.00 | -- | -- | -- | 18.09 | -48.02 | -48.02 | 4.94 | -21.18 | 0.1077 | -- | 5.86 | 681,736.80 | -106.00 | -43.66 | -122.03 | -66.84 | -- | -- | -983.83 | -136.35 | -- | -0.5249 | -- | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
| Voyager Therapeutics Inc | 119.04m | -3.04m | 469.37m | 162.00 | -- | 1.38 | 309.20 | 3.94 | -0.1812 | -0.1812 | 2.44 | 6.28 | 0.2954 | -- | 8.27 | 734,839.50 | -0.7554 | 0.6378 | -0.8534 | 0.8203 | -- | -- | -2.56 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
| Tscan Therapeutics Inc | 14.81m | -96.80m | 470.48m | 161.00 | -- | 3.47 | -- | 31.76 | -1.28 | -1.28 | 0.1784 | 2.57 | 0.0715 | -- | -- | 96,181.82 | -46.72 | -- | -52.48 | -- | -- | -- | -653.50 | -- | -- | -- | 0.1974 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
| Fate Therapeutics Inc | 6.48m | -190.05m | 471.26m | 181.00 | -- | 1.11 | -- | 72.75 | -1.92 | -1.92 | 0.0653 | 3.74 | 0.0108 | -- | 0.9024 | 35,790.05 | -31.67 | -31.82 | -34.36 | -36.05 | -- | -- | -2,933.79 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
| Larimar Therapeutics Inc | 0.00 | -45.08m | 474.05m | 42.00 | -- | 2.05 | -- | -- | -0.9666 | -0.9666 | 0.00 | 3.62 | 0.00 | -- | -- | 0.00 | -24.56 | -42.22 | -26.04 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
| Korro Bio Inc | 0.00 | -81.19m | 475.33m | 94.00 | -- | 2.72 | -- | -- | -43.16 | -43.16 | 0.00 | 18.87 | 0.00 | -- | -- | 0.00 | -54.22 | -31.55 | -60.95 | -36.48 | -- | -- | -- | -365.87 | -- | -357.64 | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
| Nkarta Inc | 0.00 | -116.20m | 480.59m | 150.00 | -- | 1.01 | -- | -- | -2.35 | -2.35 | 0.00 | 6.72 | 0.00 | -- | -- | 0.00 | -22.45 | -32.39 | -23.55 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
Data as of May 17 2024. Currency figures normalised to Cibus Inc's reporting currency: US Dollar USD
25.80%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 2.78m | 13.25% |
| Vantage Consulting Group, Inc.as of 31 Dec 2023 | 1.14m | 5.45% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 716.64k | 3.41% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 216.00k | 1.03% |
| Geode Capital Management LLCas of 31 Dec 2023 | 160.49k | 0.77% |
| Corient Private Wealth LLCas of 31 Mar 2024 | 121.72k | 0.58% |
| Glenview Capital Management LLCas of 31 Dec 2023 | 116.47k | 0.56% |
| Citigroup Global Markets, Inc. (Investment Management)as of 31 Mar 2024 | 55.95k | 0.27% |
| Old West Investment Management LLCas of 31 Mar 2024 | 51.38k | 0.25% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 50.29k | 0.24% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
